中国非小细胞肺癌患者血清DAPK基因、p16基因启动子甲基化的分析(英文)

目的分析65名中国南京军区南京总医院的非小细胞肺癌(NSCLC)住院患者血清中DAPK、p16启动子区域甲基化的改变状况及其临床意义。方法运用甲基化特异性PCR技术,检测65例NSCLC患者血清DAPK、p16基因启动子区域甲基化的改变情况,并分析与临床病理资料的关系。结果 NSCLC患者血清DAPK基因甲基化检出率为30．8％(20/65),p16基因甲基化检出率为43．1％(28/65),而正常对照组和良性肺部疾病组血清未检出DAPK基因、p16基因甲基化,DAPK基因、p16基因甲基化检出率与NSCLC病理类型、分期及转移状态无明显关系。结论 DAPK基因、p16基因检出启动子区域异常甲基化是NSCLC早期辅助诊断的分子标志物之一。

The Promoter Hypermethylation of DAPK Gene and pl6 Gene in Sera from Chinese Non-small Cell Lung Cancer Patients

Objective: To evaluate the clinical significance of the aberrant methylation of DAPK gene and pl6 gene in sera from 65 NSCLC patients from Nanjing General Hospital of Nanjing Command, China. Methods: A methylation-specific PCR (MSP) was performed for the detection of promoter hypermethy lation of DAPK gene and p16 gene in blood DNA from 65 cases of NSCLC, and to analyze the relation of the aberrant methylation of DAPK gene and pl6 gene and the clinicopathological data. Results: 30.8% (20/65) of the sera from 65 cases of NSCLC showed hypermethylation for DAPK promoter and 43.1% (28/65) the same for p16 promoter, whereas no methylated DAPK gene promoter and pl6 gene promoter were found in sera from the patients with lung benign diseases and normal controls. Methylated DAPK gene promoter and p16 gene promoter in sera were not closely correlated with the pathological classification, stage, metastasis and differentiation in NSCLC. Conclusion: Detection of the aberrant methylation of DAPK gene and pl6 gene in blood DNA from NSCLC patients might offer an effective means for the earlier auxiliary diagnosis of the malignancy.